IMCR - Immunocore Holdings - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.648B

Cash

832.8M

Avg Qtr Burn

-3.047M

Short % of Float

14.40%

Insider Ownership

5.29%

Institutional Own.

87.12%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KIMMTRAK (Tebentafusp) (gp100) Details Metastatic uveal melanoma, Melanoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-F106C (Brenetafusp) + nivolumab Details Cancer, Melanoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KIMMTRAK (Tebentafusp) +/- anti-PD1 Details Cancer, Melanoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KIMMTRAK (Tebentafusp) (gp100) Details Cancer, Metastatic uveal melanoma, Melanoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-F106C (Brenetafusp) Details Ovarian cancer, Endometrial cancer, Cancer, Breast cancer, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-F106C (Brenetafusp) +/- Pembrolizumab Details Cancer, Melanoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-C103C Details Ovarian cancer, Head and neck cancer, Cancer, Non-small cell lung carcinoma, Gastric cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-I109V Details Viral infection, Hepatocellular carcinoma, Hepatitis B	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-M113V Details Human immunodeficiency virus, Viral infection	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-R117C [PIWIL1-A02 targeted] Details Cancer, Colorectal cancer , Gastrointestinal stromal tumors	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.